The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Brian I. Rini
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Bernard J. Escudier
Honoraria - Acceleron Pharma; Bristol-Myers Squibb; Exelixis; Ipsen; Nektar; Novartis; Pfizer; Roche
 
Lawrence Fong
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology; Oncosec (Inst); Roche/Genentech (Inst)
 
Richard Wayne Joseph
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Genoptix; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech (Inst); X4 Pharma (Inst)
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Mario Sznol
Stock and Other Ownership Interests - Adaptive Biotechnologies; Amphivena; Intensity Therapeutics
Consulting or Advisory Role - Adaptimmune; Alexion Pharmaceuticals; Amgen; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Immune Design; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Lion Biotechnologies; Lycera; Merck Sharp & Dohme; Merus; Modulate Pharma; Nektar; Novartis; pfizer; Symphony Evolution; Theravance; Vaccinex
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)
 
Walter Michael Stadler
Honoraria - AstraZeneca; Bayer; CVS Caremark; Johnson & Johnson; Merck; Sotio
Consulting or Advisory Role - AstraZeneca; Bayer; CVS Caremark; Johnson & Johnson; Merck; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Other Relationship - American Cancer Society; UpToDate
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; GlaxoSmithKline; GlaxoSmithKline; Novartis; Pfizer
Speakers' Bureau - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Pfizer
Research Funding - GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Medivation (Inst); Pfizer (Inst)
 
Alain Ravaud
No Relationships to Disclose
 
Sergio Bracarda
No Relationships to Disclose
 
Cristina Suarez
No Relationships to Disclose
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
YounJeong Choi
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Patents, Royalties, Other Intellectual Property - Genentech
 
Mahrukh A. Huseni
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Gregg Daniel Fine
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Thomas Powles
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech